Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.60 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.60 |
| ▸ | TUBB | P07437 | 1/20 | 0.60 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.60 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.60 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.60 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.60 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.60 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.60 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.60 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.60 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.60 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.60 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.60 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.60 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.60 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30383733 | 1.00 | MAPT (0.63) | MAPTLMNAKDM4ECXCL12TUBB4A | |
| SCHEMBL25278517 | 1.00 | MAPT (0.63) | MAPTLMNAKDM4ECXCL12TUBB4A | |
| SCHEMBL30383691 | 1.00 | MAPT (0.63) | MAPTLMNAKDM4ECXCL12TUBB4A | |
| SCHEMBL25184985 | 1.00 | MAPT (0.63) | MAPTLMNAKDM4ECXCL12TUBB4A | |
| SCHEMBL25279664 | 0.90 | KDM4E (0.64) | MAPTLMNAKDM4ECXCL12TUBB4A | |
| SCHEMBL30382661 | 0.90 | KDM4E (0.64) | MAPTLMNAKDM4ECXCL12TUBB4A | |
| SCHEMBL25279161 | 0.89 | MAPT (0.60) | MAPTLMNAKDM4ECXCL12TUBB4A | |
| SCHEMBL30383963 | 0.89 | MAPT (0.60) | MAPTLMNAKDM4ECXCL12TUBB4A | |
| SCHEMBL25195693 | 0.87 | MAPT (0.82) | MAPTLMNAKDM4ECXCL12TUBB4A | |
| SCHEMBL25192718 | 0.87 | MAPT (0.82) | MAPTLMNAKDM4ECXCL12TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | MAPT 3297/4885LMNA 1180/4885KDM4E 1732/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885LMNA 1817/4885KDM4E 2652/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885LMNA 1817/4885KDM4E 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.